Follow The Filings

WVE Wave Life Sciences Ltd.

Health Care, filed as WAVE LIFE SCIENCES LTD (SHS), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

  • 2 Owners
  • Max 0.5%
  • $61M
  • 1 add

In 2026 Q2 Lee Ainslie added to Wave Life Sciences.

Who owns this now

Largest portfolio weights among holders, up to 0.5% (Lee Ainslie, Maverick Capital). Not free-float ownership.

  1. Lee Ainslie Add 0.53%
  2. Stanley Druckenmiller 0.02%

Who owns WVE

Sorted by value, long equity only, as of 2026 Q2.

History
Lee Ainslie, Maverick Capital 0.53% Add +1.1% 10,278,115 $60M History
Stanley Druckenmiller, Duquesne Family Office 0.02% Hold 173,000 $1M History

2 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by WVE's executives, directors and 10% owners in the last 12 months, from their Form 4s

All WVE insider trades
  • $82.6M bought by 2 insiders
  • None no sales outside a trading plan
  • $15.9M sold by 8 insiders under 10b5-1 plans
  1. Heidi L Wagner Director
    Planned sale
    $42K 7,000 shares at $6.01 14% of stake
    Traded Aug 11 Filed Aug 13
    ↗
  2. Adrian Rawcliffe Director
    Planned sale
    $67K 12,700 shares at $5.29 100% of stake
    Traded Aug 12 Filed Aug 13
    ↗
  3. Ra Capital Management, L.P. Director, +3 joint filers
    Buy
    $54.6M 8,772,496 shares at $6.23 +48% to stake
    Traded Mar 26–30 Filed Mar 30
    ↗
  4. Chris Francis See Remarks
    Planned sale
    $500K 33,194 shares at $15.05 35% of stake
    Traded Feb 26 Filed Feb 27
    ↗
  5. Chris Francis See Remarks
    Planned sale
    $150K 9,375 shares at $16.03 27% of stake
    Traded Jan 2 Filed Jan 6
    ↗
  6. GSK plc 10% owner
    Buy
    $27.9M 1,470,000 shares at $19.00 +8.8% to stake
    Traded Dec 11, 2025 Filed Dec 15, 2025
    ↗
  7. Adrian Rawcliffe Director
    Planned sale
    $630K 42,000 shares at $15.00 77% of stake
    Traded Dec 8, 2025 Filed Dec 10, 2025
    ↗
  8. Heidi L Wagner Director
    Planned sale
    $189K 14,000 shares at $13.50 24% of stake
    Traded Dec 8, 2025 Filed Dec 10, 2025
    ↗
  9. Christian O Henry Director
    Planned sale
    $1.4M 93,445 shares at $14.65 88% of stake
    Traded Dec 8, 2025 Filed Dec 10, 2025
    ↗
  10. Aik Na Tan Director
    Planned sale
    $1.8M 134,218 shares at $13.58 84% of stake
    Traded Dec 8, 2025 Filed Dec 10, 2025
    ↗
  11. Gregory L. Verdine Director
    Planned sale
    $269K 20,000 shares at $13.47 6.8% of stake
    Traded Dec 8, 2025 Filed Dec 10, 2025
    ↗
  12. Chris Francis See Remarks
    Planned sale
    $6.4M 441,031 shares at $14.57 95% of stake
    Traded Dec 8, 2025 Filed Dec 10, 2025
    ↗
  13. Kyle Moran CFO
    Planned sale
    $4.1M 260,036 shares at $15.78 74% of stake
    Traded Dec 8–9 Filed Dec 10, 2025
    ↗
  14. Mark Corrigan Director
    Planned sale
    $217K 16,115 shares at $13.48 36% of stake
    Traded Dec 8, 2025 Filed Dec 10, 2025
    ↗
  15. Ra Capital Management, L.P. Director, +3 joint filers
    Buy
    $6,688 1,000 shares at $6.69 +<0.1% to stake
    Traded Nov 13, 2025 Filed Nov 14, 2025
    ↗

Also filed in the last 12 months, not counted as buying or selling: 28 option exercises, 12 stock grants, 6 sales to cover taxes, and 1 conversion.

SEC filings

Recent issuer filings from EDGAR, 22 shown.

Filed Form Detail Links
DEF 14A Filing Doc
SCHEDULE 13D/A — Filing Doc
8-K 2.02,7.01,9.01 Filing Doc
10-Q Filing Doc
8-K 5.07 Filing Doc
8-K 7.01,8.01,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
DEF 14A Filing Doc
SCHEDULE 13G/A — Filing Doc
10-K/A Filing Doc
8-K 2.02,7.01,9.01 Filing Doc
10-Q Filing Doc
8-K 8.01,9.01 Filing Doc
DEFA14A Filing Doc
SCHEDULE 13D/A — Filing Doc
8-K 1.01,8.01,9.01 Filing Doc
DEFA14A Filing Doc
SCHEDULE 13D/A — Filing Doc
8-K 7.01,8.01,9.01 Filing Doc
8-K 2.02,7.01,9.01 Filing Doc
10-K Filing Doc
SCHEDULE 13G/A — Filing Doc

Source: SEC EDGAR submissions, updated 5 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $113.3M $108.3M $42.73M
Net income -$57.51M -$97.01M -$204.38M
Net margin * -50.8% -89.6% -478.3%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $235.37M $320.39M $614.81M
Total non-current assets $39.58M $31.81M $23.68M
Total assets $274.95M $352.21M $638.5M
Total current liabilities $186.44M $110.95M $95.06M
Total non-current liabilities $41M $23.86M $17.2M
Total equity $39.63M $209.52M $518.36M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$19.43M -$151.03M -$187.49M
Cash from investing -$1.12M -$0.938M -$0.718M
Cash from financing $132.53M $253.89M $488.24M
Net change in cash $111.89M $101.79M $300.04M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.